A somatostatin receptor agonist with a higher affinity for the somatostatin subgroup 2 receptors SST2, SST3, and SST5 (IC50s = 0.5-1.8, 43-107, and 5.6-32 nM, respectively) than for the subgroup 1 receptors, SST1 and SST4 (IC50s = 500-2,330 and 66-2,100nM, respectively); inhibits the release of growth hormone from patient-derived pituitary adenoma cells in vitro when used at a concentration of 100 nM; inhibits tumor growth in SCLC mouse xenograft models when administered at a dose of 250 μg, twice daily